Matinas BioPharma Holdings (MTNB) Invested Capital (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Invested Capital data on file, last reported at $3.0 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $3.0 million, down 51.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (down 51.82% YoY), and the FY2025 annual result was $4.8 million, down 36.41% from the prior year.
• Invested Capital eased to $3.0 million in Q1 2026 per MTNB's latest filing, from $4.8 million in the prior quarter.
• Over five years, Invested Capital peaked at $47.7 million in Q1 2022 and troughed at $3.0 million in Q1 2026.
• A 5-year average of $20.8 million and a median of $19.1 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital fell 28.38% in 2022, then slumped 60.52% in 2024.
• A 5-year view of Invested Capital shows it stood at $36.7 million in 2022, then sank by 47.45% to $19.3 million in 2023, then tumbled by 60.52% to $7.6 million in 2024, then plunged by 36.41% to $4.8 million in 2025, then plunged by 37.38% to $3.0 million in 2026.
• Business Quant data shows MTNB's Invested Capital at $3.0 million in Q1 2026, $4.8 million in Q4 2025, and $6.5 million in Q3 2025.